invest1 distinct publisher
JPMorgan's Morgan Health prices Thyme Care at 16 times its 2025 revenue
Thyme Care's valuation doubled to more than $2bn while revenue quintupled to $125m, which means Morgan Health bought in at a multiple roughly 60% below what September's Series D investors paid. The profitability behind it is self-reported.
Publishers:techfundingnews.com
Reality
- Evidence28
- Adoption55
- Hype gap+32
- Incentives74